Reply to A. Indini et al

Affiliations

¹ Memorial Sloan Kettering Cancer Center, New York, NY.
² Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY.
³ Memorial Sloan Kettering Cancer Center; Ludwig Institute for Cancer Research; and Weill Cornell Medical College, New York, NY.
⁴ Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY chapmanp@mskcc.org.

Comment

Troy Z Horvat et al. J Clin Oncol. 2016.

. 2016 Mar 20;34(9):1018-9.

doi: 10.1200/JCO.2015.65.7007. Epub 2016 Jan 19.

¹ Memorial Sloan Kettering Cancer Center, New York, NY.
² Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY.
³ Memorial Sloan Kettering Cancer Center; Ludwig Institute for Cancer Research; and Weill Cornell Medical College, New York, NY.
⁴ Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY chapmanp@mskcc.org.

No abstract available

Comment on

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB. Horvat TZ, et al. J Clin Oncol. 2015 Oct 1;33(28):3193-8. doi: 10.1200/JCO.2015.60.8448. Epub 2015 Aug 17. J Clin Oncol. 2015. PMID: 26282644 Free PMC article.
Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio.
Indini A, Di Nicola M, Del Vecchio M, De Braud F. Indini A, et al. J Clin Oncol. 2016 Mar 20;34(9):1017-8. doi: 10.1200/JCO.2015.65.0028. Epub 2016 Jan 19. J Clin Oncol. 2016. PMID: 26786928 No abstract available.